An observational study in Open Angle Glaucoma and Ocular Hypertension, sponsored by iSTAR Medical. Active, not recruiting at 9 sites in 6 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by iSTAR Medical · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Glaucoma, Open-Angle by iSTAR Medical — 1 open to participants now, 5 under way, none of them phase 3. Glaucoma, Open-Angle · iSTAR Medical.
Among the 10 studies in Glaucoma, Open-Angle by iSTAR Medical, this one is the only one that started in 2020, is one of 3 observational ones, and was the 7th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 10 studies in Glaucoma, Open-Angle by iSTAR Medical is open now, in 3 countries. Recruiting first, the newest first:
iSTAR Medical · Sites in Panama, Spain, United Kingdom
Ages 40+
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2020.
This study's enrollment of 116 is above the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Median enrollment 30 across the 7 interventional studies, 116 across the 3 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
iSTAR Medical is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
2 of the studies in Glaucoma, Open-Angle by iSTAR Medical that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04524416iSTAR MedicalMINIject Global Long-Term Follow-up Study | 2026-12 |
| NCT05024695iSTAR MedicalEvaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Glaucoma, Open-Angle by iSTAR Medical, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will assess the long-term (up to 5 years) safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a MINIject glaucoma implant.
The study aims to assess long-term safety and performance of MINIject glaucoma implant up to 5 years post-implantation. Patients who received implant and were followed for 2 years in a previous study, will be invited to continue long-term follow-up from 2 to 5 years post-implantation at annual intervals. Standard ophthalmologic assessments including measurement of intraocular pressure, fundus examination, ocular imaging, assessment of any untoward ocular events etc. will be performed.
patients with open-angle glaucoma not-controlled with hypotensive medications and who, to treat this condition, already received MINIject in a previous study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MINIject implant placed into supraciliary space. The implantation was done in a previous study in which patient participated and is not part of this study.
Proportion of patients with serious device-related adverse event in study eye
The proportion of patients with at least one serious ocular adverse event in the study eye, related to the device, occurring between 2 and 5 years after the MINIject implantation.
Time frame: 5 years post-implantation
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.
Of 53 observational studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12. This study's planned 76 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
iSTAR Medical